NASDAQ:RYTMRhythm Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.37 +1.43 (+7.55 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$19.11Now: $20.37▼$20.5550-Day Range$16.82MA: $19.19▼$20.4052-Week Range$12.99Now: $20.37▼$25.84Volume176,938 shsAverage Volume234,785 shsMarket Capitalization$898.15 millionP/E RatioN/ADividend YieldN/ABeta0.94 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.29, Rhythm Pharmaceuticals has a potential upside of 68.3% from its current price of $20.37.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesRhythm Pharmaceuticals has received 217 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRhythm Pharmaceuticals has received 215 “underperform” votes. (Add your “underperform” vote.)Community SentimentRhythm Pharmaceuticals has received 50.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote “Outperform” if you believe RYTM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,997,926.00 in company stock.Percentage Held by InsidersOnly 9.49% of the stock of Rhythm Pharmaceuticals is held by insiders.Percentage Held by Institutions92.03% of the stock of Rhythm Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.38) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM Previous Symbol CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone857-264-4280Debt Debt-to-Equity Ratio0.01 Current Ratio15.14 Quick Ratio15.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book3.18Profitability EPS (Most Recent Fiscal Year)($3.86) Net Income$-140,730,000.00 Net MarginsN/A Return on Equity-67.50% Return on Assets-60.13%Miscellaneous Employees54 Outstanding Shares44,092,000Market Cap$898.15 million Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:RYTM Rates by TradingView Receive RYTM News and Ratings via Email Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions How has Rhythm Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RYTM stock has increased by 35.8% and is now trading at $20.37. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Rhythm Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rhythm Pharmaceuticals. When is Rhythm Pharmaceuticals' next earnings date? Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Rhythm Pharmaceuticals. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced its earnings results on Monday, May, 4th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.02. View Rhythm Pharmaceuticals' earnings history. What price target have analysts set for RYTM? 7 Wall Street analysts have issued 1-year target prices for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $34.29 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View analysts' price targets for Rhythm Pharmaceuticals. Has Rhythm Pharmaceuticals been receiving favorable news coverage? News articles about RYTM stock have trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutRhythm Pharmaceuticals. Are investors shorting Rhythm Pharmaceuticals? Rhythm Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,440,000 shares, a decrease of 16.3% from the April 30th total of 1,720,000 shares. Based on an average trading volume of 246,300 shares, the days-to-cover ratio is currently 5.8 days. Currently, 4.3% of the shares of the company are short sold. View Rhythm Pharmaceuticals' Current Options Chain. Who are some of Rhythm Pharmaceuticals' key competitors? Some companies that are related to Rhythm Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Allakos (ALLK), PTC Therapeutics (PTCT), Deciphera Pharmaceuticals (DCPH), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Uniqure (QURE), Axsome Therapeutics (AXSM), Alkermes (ALKS), Insmed (INSM), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT) and Turning Point Therapeutics (TPTX). View all competitors. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Agile Therapeutics (AGRX), Amarin (AMRN), Intra-Cellular Therapies (ITCI), Exelixis (EXEL), Nabriva Therapeutics (NBRV), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Selecta Biosciences (SELB) and Sangamo Therapeutics (SGMO). Who are Rhythm Pharmaceuticals' key executives? Rhythm Pharmaceuticals' management team includes the following people: Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)Mr. Hunter C. Smith, CFO & Treasurer (Age 50)Ms. Nithya Desikan, Chief Commercial Officer (Age 40)Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)Mr. Simon D. Kelner, Chief HR Officer (Age 46) When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. What is Rhythm Pharmaceuticals' stock symbol? Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM." Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (9.80%), Primecap Management Co. CA (8.03%), Wellington Management Group LLP (6.05%), BlackRock Inc. (5.67%), Federated Hermes Inc. (5.14%) and State Street Corp (2.22%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan and Todd Foley. View institutional ownership trends for Rhythm Pharmaceuticals. Which major investors are selling Rhythm Pharmaceuticals stock? RYTM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Deutsche Bank AG, Wells Fargo & Company MN, SG Americas Securities LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, and Todd Foley. View insider buying and selling activity for Rhythm Pharmaceuticals. Which major investors are buying Rhythm Pharmaceuticals stock? RYTM stock was acquired by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Rock Springs Capital Management LP, Aviva PLC, Federated Hermes Inc., Martingale Asset Management L P, Geode Capital Management LLC, State Street Corp, and Bessemer Group Inc.. View insider buying and selling activity for Rhythm Pharmaceuticals. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Rhythm Pharmaceuticals' stock price today? One share of RYTM stock can currently be purchased for approximately $20.37. How big of a company is Rhythm Pharmaceuticals? Rhythm Pharmaceuticals has a market capitalization of $898.15 million. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe. What is Rhythm Pharmaceuticals' official website? The official website for Rhythm Pharmaceuticals is www.rhythmtx.com. How can I contact Rhythm Pharmaceuticals? Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
